HBC Hofseth Biocare

Hofseth Biocare ASA: PROXY RIGHTS AT GENERAL MEETING

Hofseth Biocare ASA: PROXY RIGHTS AT GENERAL MEETING

Ola Holen, chairman of the Board of Hofseth BioCare ASA (the "Company" or "HBC"), has in connection with the upcoming extraordinary general meeting on 11 November 2020, received proxy rights without voting instructions from shareholders representing 43,319,914 shares in the Company, equal to approx. 12.21% of the voting rights.

Mr. Holen owns as of the date hereof a total of 1,465,253 shares, equal to 0.41 per cent of the outstanding shares in HBC. 935,388 shares are owned via his fully owned company, Paso AS, and 529,865 shares are held privately.

After the receipt of the above-mentioned proxies, Mr. Holen represents a total of 44,785,167 shares and votes, equal to 12.62% of the voting rights at the upcoming extraordinary general meeting in HBC on 11 November 2020.

For further information, please contact:

Jon Olav Ødegård, CFO of Hofseth BioCare ASA

Mob:

E-mail:

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that develops high-value ingredients and finished products. Ingredients are further developed into discovery and pre-clinical studies in multiple clinics and university research labs in several countries. Lead clinical and pre-clinical candidates are development towards a Gastro-Intestinal (GI) Protective Medical Food, Medical Food to help treat age-related Sarcopenia, and future phase 1 studies on treatment of Anemia and NEC-IBD with Salmon Protein Hydrolysate fractions.

The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts. Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, Chicago, Mumbai, Palo Alto and Tokyo.

HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at hofsethbiocare.com and facebook.com/hofsethbiocare

This information is subject to the disclosure requirements pursuant to Sections 4-3 and 5-12 of the Norwegian Securities Trading Act

EN
09/11/2020

Underlying

HBCHofseth Biocare

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: FOURTH QUARTER 2025 FINANCIAL REPORT

Hofseth BioCare ASA: FOURTH QUARTER 2025 FINANCIAL REPORT HBC recorded total operating revenues of NOK 72.2 million in the fourth quarter of 2025, compared to NOK 64.9 million in the same period last year. Net operating revenues were NOK 71.1 million, up from NOK 64.9 million in Q4 2024. Full year 2025, total operating revenues amounted to NOK 256.3 million (265.5). Total operating revenue in 2024 included NOK 8.1 million of gain on sale of assets. EBITDA for the quarter was negative NOK 26.5 million, compared to negative NOK 26.1 million in Q4 2024. For full year 2025, EBITDA was negative...

February 13, 2026 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Notification of major shareholdings

Notification of major shareholdings Effective February 9, 2026, the “Bonafide Investment Fund – Best Catches I” made a subscription in kind to the “Bonafide Investment Fund – HBC II”. Following the subscription in kind, the Bonafide Investment Fund – Best Catches I no longer holds shares in Hofseth Biocare ASA. According to the information published on the website of the Oslo Stock Exchange, the total number of outstanding shares of Hofseth Biocare ASA currently amounts to 395,081,030. Based on this figure, IFM Independent Fund Management AG will hold a total of 16.62% of the voting rights...

February 11, 2026 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: Cancellation of Subsequent Offering – Update on c...

Hofseth BioCare ASA: Cancellation of Subsequent Offering – Update on completion of Private Placement NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to previous announcements by Hofseth BioCare ASA (the "Company") regarding a subsequent offering with gross proceeds of up to approx. NOK 30,000,000 throug...

December 15, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION

Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC"), has subscribed for 368,320 Offer shares in the Subsequent Offering and Mr. Baldegger will hold 3,616,296 shares in HBC after the share capital is registered, equal to approximately 0.92 % of the total outstanding A-shares with voting rights.  For further information, contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: E-mail: This information is subject to the disclosure requirements in the Market Abuse Regulation EU 596/20...

November 21, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING

Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to previous announcements by Hofseth BioCare ASA (the "Company") regarding a subsequent offering with gross proceeds of up to approx. NOK 30,000,000 through issuance of up to 16,666,666 new ordinary share...

November 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch